The Hope and Hype of Precision Medicine: A Health Policy and Bioethics Consortium
There has been considerable hype surrounding personalized and precision medicine in the past few years-including President Obama's 2015 announcement of $215 million for the Precision Medicine Initiative. While some policymakers hail this movement as a pending revolution in healthcare, other commentators are skeptical, arguing that the same funding directed toward the social and behavioral determinants of health would yield far greater gains in terms of patient benefits and healthcare savings.
How important is precision medicine for our healthcare marketplace, and what should the expected outcomes be for public investment in research in this area?
This event was free and open to the public.
Sandro Galea, MD, MPH, DrPH, Dean and Robert A. Knox Professor, Boston University School of Public Health
Calum A. MacRae, MD, PhD, Chief of Cardiovascular Medicine, Brigham and Women's Hospital
Moderator: Spencer Hey, PhD, Faculty, Harvard Center for Bioethics
Learn more about the Health Policy and Bioethics Consortia.
The Health Policy and Bioethics Consortia are hosted and organized by the Harvard Medical School Center for Bioethics and the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Harvard Program in Therapeutic Science. This monthly series convenes international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. Support provided by the Oswald DeN. Cammann Fund at Harvard University.